Elhadd Tarik, Gul Wajiha, Dabbous Zeinab, Beer Stephen, Bashir Mohammed
Endocrine Section, Department of Medicine, Hamad Medical Corporation, Doha, Qatar E-mail:
Qatar Med J. 2022 Aug 5;2022(3):39. doi: 10.5339/qmj.2022.39. eCollection 2022.
COVID-19 infection has been spreading across the globe since the end of 2019, and it continues to cause chronic multi-system sequelae, of which thyroid dysfunction appears to be the major one. We have discussed here 10 cases of thyroid dysfunction after COVID-19 infection.
Case series report. From October 2020 to July 2021, a series of 10 cases of thyroid dysfunction after COVID-19 infection were recorded and managed in a single outpatient endocrine center in Doha, Qatar.
We have reported 5 cases of Graves's hyperthyroidism, 2 of chronic primary hypothyroidism (including one with Grave's disease [GD]) who was treated through radioactive iodine (RAI) therapy, one case of subacute thyroiditis, one case with "Sick euthyroid disease," and one case of central hypothyroidism. Presently, patients with GD are being treated with carbimazole and those with hypothyroidism are being treated with levothyroxine. The remaining patients had recovered with euthyroid.
This is the largest case series reported from a single center to date. The findings of this series indicate a bimodal distribution of thyroid dysfunction in patients with COVID-19 infection. A review of the literature and discussion of potential pathophysiological mechanisms has been presented. We have emphasized the importance of screening for thyroid dysfunction in "post-COVID-19" cases, considering that the prevalence may be underestimated.
自2019年底以来,新型冠状病毒肺炎(COVID-19)感染一直在全球蔓延,并且它继续导致慢性多系统后遗症,其中甲状腺功能障碍似乎是主要的一种。我们在此讨论了10例COVID-19感染后的甲状腺功能障碍病例。
病例系列报告。2020年10月至2021年7月,卡塔尔多哈的一个门诊内分泌中心记录并管理了一系列10例COVID-19感染后的甲状腺功能障碍病例。
我们报告了5例格雷夫斯氏甲状腺功能亢进症、2例慢性原发性甲状腺功能减退症(包括1例接受放射性碘(RAI)治疗的格雷夫斯病[GD])、1例亚急性甲状腺炎、1例“病态甲状腺综合征”和1例中枢性甲状腺功能减退症。目前,GD患者正在接受卡比马唑治疗,甲状腺功能减退症患者正在接受左甲状腺素治疗。其余患者甲状腺功能恢复正常。
这是迄今为止单个中心报告的最大病例系列。该系列的研究结果表明,COVID-19感染患者的甲状腺功能障碍呈双峰分布。本文对文献进行了综述,并讨论了潜在的病理生理机制。我们强调了在“COVID-19后”病例中筛查甲状腺功能障碍的重要性,因为其患病率可能被低估。